On July 1, 2024, Director B Parshall sold 5,000 shares of Cytokinetics Inc (NASDAQ:CYTK) at a price of $54.22 per share, as reported in the SEC Filing. Following this transaction, the insider now owns 20,600 shares of the company. Warning! GuruFocus has detected 9 Warning Signs with CYTK. Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. This recent sale continues a trend observed within the company, where there have been 42 insider sells and no insider buys over the past year. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion. According to the GF Value, the intrinsic value estimate for the stock is $3.15, indicating a price-to-GF-Value ratio of 17.21. This suggests that the stock is significantly overvalued. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts. Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) This insider sale might be of interest to investors tracking insider behaviors as an indicator of potential stock performance, particularly in light of the company's current valuation status. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...